Liraglutide Pilot Study Explores Reducing Parenteral Support in Short Bowel Syndrome Patients

Short Bowel Syndrome (SBS) is a severe condition leading to malabsorption and often requiring parenteral support (intravenous nutrition). Current standard-of-care includes glucagon-like peptide-2 (GLP-2) analogues like teduglutide, which improve intestinal adaptation and reduce parenteral support. However, exploring other gut-trophic peptides is crucial. Glucagon-like peptide-1 (GLP-1) agonists, known for their metabolic effects, also influence gut motility and nutrient absorption, presenting a potential novel therapeutic avenue for SBS patients.

This pilot study, named SLIPS, investigated the effect of liraglutide 3 mg daily (QD) on reducing parenteral support in patients diagnosed with short bowel syndrome. Subjects were titrated up to the 3 mg QD dose and maintained it for a 52-week intervention period. A placebo-controlled design was employed, with a comparator arm receiving liraglutide 3 mg placebo QD. The primary objective was to assess the potential for liraglutide to decrease dependence on intravenous nutrition in this patient population.

The provided abstract outlines the study's design and objectives but does not include any specific findings or numerical results from the intervention. This pilot study aims to assess the effect of liraglutide on parenteral support reduction in short bowel syndrome patients over a 52-week period. As such, no specific percentages, p-values, or fold-changes regarding efficacy or safety can be reported from this abstract.